Advertisement

Geriatric Assessment for the Oncologist

  • Allison Magnuson
  • Supriya MohileEmail author
Chapter

Abstract

The incidence of cancer, particularly gynecologic malignancy, increases with advanced age. The geriatric population is a heterogeneous group, and a patient’s chronologic age does not always reflect their overall health status. Therefore, oncologists need to be adept at assessing physiologic and functional capacity in older patients. The comprehensive geriatric assessment is the gold standard for evaluation of the geriatric patient. The various components of the CGA have been shown to influence cancer-related therapy in a multitude of ways, as previously discussed. The combined data from the CGA can be used to stratify patients into risk categories to better predict their tolerance to treatment and risk for chemotherapy toxicity. However, the CGA is a comprehensive tool requiring significant time and training to perform. Therefore, a variety of screening tools have been developed which may be useful in the general oncology practice setting to identify patients that may benefit from further testing and intervention. Further research is still needed to evaluate whether these screening tools can predict cancer-related outcomes in older patients.

Keywords

Geriatric assessment Gynecologic cancers Function Disability 

References

  1. 1.
    Repetto L, Balducci L. A case for geriatric oncology. Lancet Oncol. 2002;3(5):289–97.PubMedCrossRefGoogle Scholar
  2. 2.
    Yancik R, Ries LG, Yates JW. Ovarian cancer in the elderly: an analysis of surveillance, epidemiology, and end results program data. Am J Obstet Gynecol. 1986;154(3):639–47.PubMedGoogle Scholar
  3. 3.
    Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Freyer G, Geay JF, Touzet S, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16(11):1795–800.PubMedCrossRefGoogle Scholar
  5. 5.
    Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2008. Bethesda: National Cancer Institute. http://seer.cancer.gov/csr/1975_2008/ . 2011.
  6. 6.
    Steiner E, Eicher O, Sagemuller J, et al. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer. 2003;13(2):197–203.PubMedCrossRefGoogle Scholar
  7. 7.
    Yoney A, Yildirim C, Isikli L, Unsal M. Prognostic factors and treatment outcomes in patients with operated endometrial cancer: analysis of 674 patients at a single institution. J BUON. 2011;16(1):64–73.PubMedGoogle Scholar
  8. 8.
    Wright JD, Lewin SN, Barrena Medel NI, et al. Endometrial cancer in the oldest old: tumor characteristics, patterns of care, and outcome. Gynecol Oncol. 2011;122(1):69–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Chan JK, Urban R, Cheung MK, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95(10):1314–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol. 2003;102(1):156–61.PubMedCrossRefGoogle Scholar
  11. 11.
    Villella J, Chalas E. Optimising treatment of elderly patients with ovarian cancer: improving their enrollment in clinical trials. Drugs Aging. 2005;22(2):95–100.PubMedCrossRefGoogle Scholar
  12. 12.
    Reuben DB, Rubenstein LV, Hirsch SH, Hays RD. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med. 1992;93(6):663–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20(2):494–502.PubMedCrossRefGoogle Scholar
  14. 14.
    Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of Adl: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.PubMedCrossRefGoogle Scholar
  16. 16.
    Wedding U, Rohrig B, Klippstein A, Pientka L, Hoffken K. Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol. 2007;133(12):945–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Patel KV, Peek MK, Wong R, Markides KS. Comorbidity and disability in elderly Mexican and Mexican American adults: findings from Mexico and the southwestern United States. J Aging Health. 2006;18(2):315–29.PubMedCrossRefGoogle Scholar
  18. 18.
    Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005;23(28):6865–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Audisio RA, Ramesh H, Longo WE, Zbar AP, Pope D. Preoperative assessment of surgical risk in oncogeriatric patients. Oncologist. 2005;10(4):262–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.PubMedGoogle Scholar
  21. 21.
    Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80(7):1273–83.PubMedCrossRefGoogle Scholar
  22. 22.
    Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel Jr EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000;35(3):181–200.PubMedCrossRefGoogle Scholar
  24. 24.
    Yancik R, Havlik RJ, Wesley MN, et al. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol. 1996;6(5):399–412.PubMedCrossRefGoogle Scholar
  25. 25.
    Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120(2):104–10.PubMedGoogle Scholar
  26. 26.
    Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82(11):2123–34.PubMedCrossRefGoogle Scholar
  27. 27.
    Wildes TM, Augustin KM, Sempek D, et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(7):840–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Arias E. United states life tables, 2003. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. Nat Vital Stat Syst. 2006;54(14):1–40.Google Scholar
  29. 29.
    Walters SJ, Campbell MJ, Lall R. Design and analysis of trials with quality of life as an outcome: a practical guide. J Biopharm Stat. 2001;11(3):155–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Barnett MJ, Perry PJ, Langstaff JD, Kaboli PJ. Comparison of rates of potentially inappropriate medication use according to the Zhan criteria for VA versus private sector medicare HMOs. JMCP. 2006;12(5):362–70.PubMedGoogle Scholar
  31. 31.
    Blalock SJ, Byrd JE, Hansen RA, et al. Factors associated with potentially inappropriate drug utilization in a sample of rural community-dwelling older adults. Am J Geriatr Pharmacother. 2005;3(3):168–79.PubMedCrossRefGoogle Scholar
  32. 32.
    Bregnhoj L, Thirstrup S, Kristensen MB, Bjerrum L, Sonne J. Combined intervention programme reduces inappropriate prescribing in elderly patients exposed to polypharmacy in primary care. Eur J Clin Pharmacol. 2009;65(2):199–207.PubMedCrossRefGoogle Scholar
  33. 33.
    Buck MD, Atreja A, Brunker CP, et al. Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health records. Am J Geriatr Pharmacother. 2009;7(2):84–92.PubMedCrossRefGoogle Scholar
  34. 34.
    Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24.PubMedCrossRefGoogle Scholar
  35. 35.
    Nahin RL, Fitzpatrick AL, Williamson JD, Burke GL, Dekosky ST, Furberg C. Use of herbal medicine and other dietary supplements in community-dwelling older people: baseline data from the ginkgo evaluation of memory study. J Am Geriatr Soc. 2006;54(11):1725–35.PubMedCrossRefGoogle Scholar
  36. 36.
    Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001;35(5):539–45.PubMedCrossRefGoogle Scholar
  37. 37.
    He SM, Yang AK, Li XT, Du YM, Zhou SF. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol. 2010;6(10):1195–213.PubMedCrossRefGoogle Scholar
  38. 38.
    Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428–37.PubMedCrossRefGoogle Scholar
  39. 39.
    Vinks TH, Egberts TC, de Lange TM, de Koning FH. Pharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trial. Drugs Aging. 2009;26(2):123–33.PubMedCrossRefGoogle Scholar
  40. 40.
    Crotty M, Rowett D, Spurling L, Giles LC, Phillips PA. Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial. Am J Geriatr Pharmacother. 2004;2(4):257–64.PubMedCrossRefGoogle Scholar
  41. 41.
    Plassman BL, Langa KM, McCammon RJ, et al. Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol. 2011;70(3):418–26.PubMedCrossRefGoogle Scholar
  42. 42.
    Dees EC, O’Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest. 2000;18(6):521–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344(15):1111–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Hess LM, Chambers SK, Hatch K, et al. Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. J Support Oncol. 2010;8(6):252–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and ­mortality in cancer patients: a meta-analysis. Cancer. 2009;115(22):5349–61.PubMedCrossRefGoogle Scholar
  46. 46.
    Kanesvaran R, Li H, Koo KN, Poon D. Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol. 2011;29(27):3620–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279(8):585–92.PubMedCrossRefGoogle Scholar
  48. 48.
    Diehr P, Bild DE, Harris TB, Duxbury A, Siscovick D, Rossi M. Body mass index and mortality in nonsmoking older adults: the Cardiovascular Health Study. Am J Public Health. 1998;88(4):623–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Moore KN, Frank SG, Alward EK, et al. Adjuvant chemotherapy for the “oldest old” ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009;115(7):1472–80.PubMedCrossRefGoogle Scholar
  51. 51.
    Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999;15(2):116–22.PubMedCrossRefGoogle Scholar
  52. 52.
    Seeman TE, Berkman LF, Kohout F, Lacroix A, Glynn R, Blazer D. Intercommunity variations in the association between social ties and mortality in the elderly. A comparative analysis of three communities. Ann Epidemiol. 1993;3(4):325–35.PubMedCrossRefGoogle Scholar
  53. 53.
    Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol. 2006;24(7):1105–11.PubMedCrossRefGoogle Scholar
  54. 54.
    Osborne C, Ostir GV, Du X, Peek MK, Goodwin JS. The influence of marital status on the stage at diagnosis, treatment, and survival of older women with breast cancer. Breast Cancer Res Treat. 2005;93(1):41–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.PubMedCrossRefGoogle Scholar
  56. 56.
    Ingram SS, Seo PH, Martell RE, et al. Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J Clin Oncol. 2002;20(3):770–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Hurria A, Lachs MS, Cohen HJ, Muss HB, Kornblith AB. Geriatric assessment for oncologists: rationale and future directions. Crit Rev Oncol Hematol. 2006;59:211–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998–2005.PubMedCrossRefGoogle Scholar
  59. 59.
    Hurria A. Incorporation of geriatric principles in oncology clinical trials. J Clin Oncol. 2007;25(34):5350–1.PubMedCrossRefGoogle Scholar
  60. 60.
    Molina-Garrido MJ, Guillen-Ponce C. Overvaluation of the vulnerable elders survey-13 as a screening tool for vulnerability. J Clin Oncol. 2011;29(23):3201–2; author reply 3202–3.PubMedCrossRefGoogle Scholar
  61. 61.
    Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224–37.PubMedCrossRefGoogle Scholar
  62. 62.
    Saliba D, Orlando M, Wenger NS, Hays RD, Rubenstein LZ. Identifying a short functional disability screen for older persons. J Gerontol A Biol Sci Med Sci. 2000;55(12):M750–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Saliba D, Elliott M, Rubenstein LZ, et al. The vulnerable elders survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49(12):1691–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Min LC, Elliott MN, Wenger NS, Saliba D. Higher vulnerable elders survey scores predict death and functional decline in vulnerable older people. J Am Geriatr Soc. 2006;54(3):507–11.PubMedCrossRefGoogle Scholar
  65. 65.
    Min L, Yoon W, Mariano J, et al. The vulnerable elders-13 survey predicts 5-year functional decline and mortality outcomes in older ambulatory care patients. J Am Geriatr Soc. 2009;57(11):2070–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Wenger NS, Solomon DH, Roth CP, et al. The quality of medical care provided to vulnerable community-dwelling older patients. Ann Intern Med. 2003;139(9):740–7.PubMedGoogle Scholar
  67. 67.
    Min LC, Wenger NS, Reuben DB, Saliba D. A short functional survey is responsive to changes in functional status in vulnerable older people. J Am Geriatr Soc. 2008;56(10):1932–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Mohile SG, Xian Y, Dale W, et al. Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst. 2009;101(17):1206–15.PubMedCrossRefGoogle Scholar
  69. 69.
    Mohile SG, Bylow K, Dale W, et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007;109(4):802–10.PubMedCrossRefGoogle Scholar
  70. 70.
    Luciani A, Ascione G, Bertuzzi C, et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol. 2010;28(12):2046–50.PubMedCrossRefGoogle Scholar
  71. 71.
    Falci C, Brunello A, Monfardini S. Detecting functional impairment in older patients with cancer: is vulnerable elders survey-13 the right prescreening tool? An open question. J Clin Oncol. 2010;28(32):e665–6; author reply e667.PubMedCrossRefGoogle Scholar
  72. 72.
    Kellen E, Bulens P, Deckx L, et al. Identifying an accurate pre-screening tool in geriatric oncology. Crit Rev Oncol Hematol. 2010;75(3):243–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Steverink N, Slaets J, Schuurmans H, et al. Measuring frailty: developing and testing the GFI (Groningen Frailty Indicator). Gerontologist. 2001;41:236.Google Scholar
  74. 74.
    Metzelthin SF, Daniels R, van Rossum E, de Witte L, van den Heuvel WJ, Kempen GI. The psychometric properties of three self-report screening instruments for identifying frail older people in the community. BMC Public Health. 2010;10:176.PubMedCrossRefGoogle Scholar
  75. 75.
    Schrijvers D, Baitar A, De Vos M, et al. Evaluation of the groningen frailty index (GFI) as a screening tool in elderly patients (pts): an interim analysis. http://www.cancer.gov/clinicaltrials/search/view/print?cdrid=658351&version=HealthProfessional . 2009.
  76. 76.
    Aaldriks AA, Maartense E, le Cessie S, et al. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol. 2011;79(2):205–12.PubMedCrossRefGoogle Scholar
  77. 77.
    Biesma B, Wymenga AN, Vincent A, et al. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol. 2011;22(7):1520–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Pol RA, van Leeuwen BL, Visser L, et al. Standardised frailty indicator as predictor for postoperative delirium after vascular surgery: a prospective cohort study. Eur J Vasc Endovasc Surg. 2011;42(6):824–30.PubMedCrossRefGoogle Scholar
  79. 79.
    Farinella E, LaMura F, Cirocchi R, et al. Preoperative risk estimation for onco-geriatric patients (PREOP) – a preoperative assessment of elderly surgical patients. BMC Geriatr. 2009;9 Suppl 1:94.CrossRefGoogle Scholar
  80. 80.
    Bauer JM, Kaiser MJ, Anthony P, Guigoz Y, Sieber CC. The Mini Nutritional Assessment –i ts history, today’s practice, and future perspectives. Nutr Clin Pract. 2008;23(4):388–96.PubMedCrossRefGoogle Scholar
  81. 81.
    Soubeyran P, Bellera C, Goyard J, et al. Validation of the G8 screening tool in geriatric oncology: the ONCODAGE project. J Clin Oncol. 2011;29(suppl): abstr 9001.Google Scholar
  82. 82.
    Hurria A, Mohile S, Lichtman S, et al. Geriatric assessment of older adults with cancer: baseline data from a 500 patient multi-center study. Paper presented at: American Society of Clinical Oncology, Orlando, 1 June 2009.Google Scholar
  83. 83.
    Hurria A, Togawa K, Mohile S, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective 500 patient multicenter study. Paper presented at: American Society of Clinical Oncology, Chicago; 2010.Google Scholar
  84. 84.
    Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–86. Epub 2011 Nov 9.PubMedCrossRefGoogle Scholar
  85. 85.
    Audisio RA, Pope D, Ramesh HS, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol. 2008;65(2):156–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Rochester Medical Center, University of RochesterRochesterUSA

Personalised recommendations